REFLab’s vision is to provide excellent and flexible analytical service to our customers, in order to ensure the best possible basis for diagnosis and thus optimal treatment of allergic disorders and autoreactive urticaria.
In collaboration with the pharmaceutical industry, we aim to be a trustworthy partner in the development of new methods for diagnosis and medical treatment.
We consider manufacturing of high quality products as a key factor to maintain and expand a leading position in the market, and continuously ensure customers satisfaction.
DANAK is a part of the ILAC Mutual Recognition Arrangement (MRA) inspection, that has been established and evaluated in the tree recognized regional cooperation bodies of ILAC, namely APLAC (www.aplac.org), EA (www.european-accreditation.org and IAAC (www.iaac.org.mx).
Each signatory to the ILAC MRA recognizes the accreditation and results of an inspection body accredited by another signatory, as it were one of its owns accredited inspections bodies.
For the scope of development, manufacturing and sales of products for clinical diagnostics, REFLab is certified in accordance with ISO 9001 and ISO 13485 and hence entitled to market CE labelled in-vitro diagnostic product, cf. the EC Directive 98/79/EF.